Avalo Therapeutics(AVTX)
Search documents
Avalo Therapeutics(AVTX) - 2020 Q1 - Quarterly Report
2020-05-07 20:04
Table of Contents Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value CERC Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10‑Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 CERECOR INC. (E ...
Avalo Therapeutics(AVTX) - 2019 Q4 - Annual Report
2020-03-11 20:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______to______ Commission File No. 001‑37590 Cerecor Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdi ...
Avalo Therapeutics(AVTX) - 2019 Q3 - Quarterly Report
2019-11-14 21:05
Table of Contents Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value CERC Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10‑Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 CERECOR INC ...
Avalo Therapeutics(AVTX) - 2019 Q2 - Quarterly Report
2019-08-08 20:24
Table of Contents Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value CERC Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10‑Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 CERECOR INC. (Ex ...
Avalo Therapeutics(AVTX) - 2019 Q1 - Quarterly Report
2019-05-09 20:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10‑Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 CERECOR INC. (Exact name of registrant as specified in its charter) | --- | --- | |--------------------------------------------------|-------| | | | | ...
Avalo Therapeutics(AVTX) - 2018 Q4 - Annual Report
2019-03-18 20:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______to______ Commission File No. 001‑37590 Cerecor Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdi ...